Research Stage • Building Innovation

Developing
Next-Gen BV Treatment

Developing a dissolvable, mucoadhesive vaginal film delivering standardized plant-derived antibiofilm compounds to eradicate BV pathogens while preserving beneficial Lactobacillus—a microbiome-friendly alternative to antibiotics.

Pre-Seed
Current Stage
Research
Product Development
2027
Target Clinical Trial

Seeking Strategic Partners & Advisors

Research Institutions
Industry Experts
Angel Investors
Biotech Mentors

BV Affects 1 in 3 Women

Current treatments fail to address the root cause, leading to recurrence rates above 50%

⚠️

Antibiotic Resistance

Traditional treatments contribute to growing antibiotic resistance, a global health crisis.

🔄

High Recurrence

Over 50% of women experience BV recurrence within 12 months of antibiotic treatment.

🦠

Biofilm Formation

Pathogenic bacteria form protective biofilms that resist conventional antibiotics.

Research-Driven Innovation

We're developing a mucoadhesive vaginal film that delivers standardized plant-derived compounds to disrupt biofilms while preserving beneficial Lactobacillus species.

Dissolvable Film Technology

Mucoadhesive matrix designed for extended vaginal residence time and controlled release.

Plant-Derived Compounds

Standardized botanical antibiofilm agents targeting pathogenic bacteria selectively.

Microbiome Preservation

Designed to eradicate pathogens while promoting beneficial Lactobacillus growth.

Development Targets

Target Efficacy 85%+
Biofilm Disruption Goal 90%+
Recurrence Target <20%

*Research phase development targets

How It Will Work

Our proposed mechanism for targeting and eliminating bacterial biofilms

Research Concept

Mechanism of Action • Development Phase

In Development
Pre-Clinical
Patent Pending

Development Roadmap

Targeted Delivery

Mucoadhesive polymers for precise vaginal application

Natural Compounds

Plant-derived antibiofilm agents work synergistically

Extended Release

Designed for continuous therapeutic coverage

Low Irritancy

Microbiome-sparing formulation for gentle treatment

Our Technology Platform

Combining pharmaceutical precision with botanical science

Smart Delivery System

Developing pH-responsive mucoadhesive polymers to maximize epithelial contact and drug residence time.

  • Controlled release kinetics
  • Moisture-activated dissolution
  • Extended therapeutic window

Bioactive Compounds

Researching standardized botanical extracts that work synergistically to disrupt biofilms and restore healthy vaginal flora.

  • Biofilm disruption mechanisms
  • Selective antimicrobial activity
  • Lactobacillus preservation

Why FemiShield

Non-Antibiotic

Avoiding antibiotic resistance concerns while targeting BV effectively.

Targeted Action

Designed to disrupt pathogenic biofilms while promoting beneficial flora.

Extended Release

Mucoadhesive delivery system for sustained therapeutic levels.

Plant-Derived

Natural compounds offering safety and efficacy without synthetic risks.

Research-Based

Developing evidence-based formulations with rigorous scientific validation.

Microbiome-Friendly

Preserving beneficial bacteria while eradicating pathogens.

Interested in Our Research?

We're seeking partners, advisors, and investors to help bring this innovative treatment to market. Contact us to learn more about collaboration opportunities.